Results 71 to 80 of about 18,115 (178)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management

, 2014
Gazala Khan,1 Rebecca A Moss,2 Fadi Braiteh,3,4 Marc Saltzman5 1Department of Hematology and Oncology, Henry Ford Hospital, Detroit, MI, USA; 2Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA ...
Khan G, Braiteh F, Moss RA, Saltzman M
core  

Massive Proteinuria which Rapidly Resolved after Discontinuation of Regorafenib

, 2021
: Regorafenib is treatment option of cancers. It is associated with several adverse effects, including proteinuria. We report a massive proteinuria associated with regorafenib which resolved quickly after discontinuation of the drug.
Kurtkulagi, Ozge, Atak, Burcin Meryem, Bilgin, Satilmis, Savli, Haluk, Duman, Tuba Taslamacioglu, Ozcil, Irem Emir, Kocak, Mehmet Zahid, Aktas, Gulali   +7 more
core  

Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases [PDF]

, 2019
Regorafenib (Stivarga) is an oral small molecule kinase inhibitor used to treat metastatic colorectal cancer, hepatocellular carcinomas, and gastrointestinal stromal tumors.
Walton, William G., Ervin, Samantha M., James, Lindsey I., Hanley, Ronan P., Bhatt, Aadra P., Redinbo, Matthew R., Pearce, Kenneth H., Lim, Lauren   +7 more
core   +2 more sources

Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation

Advanced Science, Volume 13, Issue 52, 18 September 2026.
This review redefines radiotherapy‐triggered drug delivery systems through structural disassembly and molecular actuation, proposing a translation‐oriented framework for dose‐correlated activation to advance clinically integrated precision oncology. ABSTRACT Radiotherapy‐triggered drug delivery systems (RDDS) promise to integrate the spatial precision ...
Jianv Jiang, Tanfeng Zhang, Junliang Dong, Wenjing Sun   +3 more
wiley   +1 more source

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

Journal of Medical Case Reports, 2017
Background Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies.
Kenji Yoshino, Dai Manaka, Ryo Kudo, Shunpei Kanai, Eisei Mitsuoka, Satoshi Kanto, Shinya Hamasu, Sayuri Konishi, Ryuta Nishitai   +8 more
doaj   +1 more source

Prognostic Impact of Metastasis Timing in Metastatic Gastrointestinal Stromal Tumors: A Multicenter Retrospective Cohort Study

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1663-1672, September 2026.
ABSTRACT Background Gastrointestinal stromal tumors (GISTs) commonly metastasize to the liver and peritoneum. Metastases may be detected synchronously at the time of initial diagnosis or develop metachronously after curative‐intent resection. Nonetheless, the prognostic significance of metastasis timing in advanced GIST remains unclear.
Kunihiko Kawai, Tsuyoshi Takahashi, Ryugo Teranishi, Shinsuke Sato, Yukinori Kurokawa, Toshirou Nishida, Seiichi Hirota, Jyunya Fujita, Yuichiro Doki, Toshimasa Tsujinaka   +9 more
wiley   +1 more source

Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy

Drug Design, Development and Therapy, 2023
Beibei Xu,1 Dong Lu,1,2 Kaicai Liu,3 Weifu Lv,2 Jingkun Xiao,2 Xingming Zhang,2 Zhengfeng Zhang,2 Jie Chai,2 Lijun Wang2 1School of Graduate, Bengbu Medical College, Bengbu, 233030, People’s Republic of China; 2Department of Interventional Radiology, The
Xu B, Lu D, Liu K, Lv W, Xiao J, Zhang X, Zhang Z, Chai J, Wang L   +8 more
doaj  

Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
This study prospectively evaluated the efficacy and safety of the bevacizumab, nab‐paclitaxel and platinum combination as a second‐line therapy for driver‐gene‐negative advanced non‐squamous non‐small cell lung cancer after immunochemotherapy. The confirmed objective response rate was 46.4%.
Ying Lin, Yunbo Yu, Zhihuang Hu, Chenchen Wei, Zezhou Wang, Yao Zhang, Zhenhua Wu, Bo Yu, Xinmin Zhao, Hui Yu, Xianghua Wu, Huijie Wang, Jialei Wang   +12 more
wiley   +1 more source

EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma

Frontiers in Medicine
BackgroundRegorafenib, a tyrosine kinase inhibitor (TKI), is used in the treatment of unresectable hepatocellular carcinoma (HCC). However, the occurrence of acquired resistance limits its antitumor efficacy.
Lili Hu, Lili Hu, Weiwei Shi, Weiwei Shi, Kua Liu, Ding Ma, Qilei Xin, Zhongxia Wang, Yin Cao, Yin Cao, Guang Zhang, Guang Zhang   +11 more
doaj   +1 more source

Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild‐type metastatic colorectal cancer: A nonrandomised clinical trial

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
For patients with refractory mCRC and preserved RAS/BRAF wild‐type status, ctDNA‐guided rechallenge of cetuximab combined with irinotecan represents a viable therapeutic avenue, offering durable disease control without compromising tolerability. Our findings underscore that optimising the screening time interval is crucial for maximising therapeutic ...
De‐Shen Wang, Wen‐Chuan Chen, Chao Ren, Feng‐Hua Wang, Zhi‐Qiang Wang, Hui‐Yan Luo, Feng Wang, Qiong Tan, Yu‐Hong Li   +8 more
wiley   +1 more source